We are excited to announce that BTG is now officially part of Boston Scientific. By merging our leading interventional oncology, venous and arterial portfolios, as well as our continuing investment in clinical science and medical education, we are positioned to be a complete clinical partner for our physicians. More importantly, as one organization, we can advance vascular and cancer solutions for more patients around the world.
“Through our combination of innovative products, people, and best-in-class capabilities, physicians will be able to extend and improve the lives of more people around the world”
Jane Healy
VP, Peripheral Interventions EMEA
Interventional Oncology
Boston Scientific can now provide interventional radiologists with tools for access and delivery, therapeutic technologies designed to extend and improve life, and clinical evidence to improve patient access to these therapies.
Venous
Boston Scientific can now expand the treatment of venous disease, including technology and clinical leadership in the interventional treatment of deep vein thrombosis, pulmonary embolism and deep venous obstruction.
Arterial
Boston Scientific’s best-in-class arterial portfolio offers differentiated drug-eluting technologies backed by unparalleled clinical evidence, along with a full set of core products to help interventionalists treat the toughest PAD and CLI cases.
Press Release
View the global announcement about Boston Scientific and BTG joining forces.
Stay up-to-date
Receive emails on the latest advances, news and innovations in interventional radiology.